License, Acquisitions and Other Agreements - ALS Biopharma Agreement (Details)	1 Months Ended	12 Months Ended
	Aug. 31, 2015 claim prodrug	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
License agreements
Milestone payment to be paid upon regulatory achievement		$ 701,975,000
Research and development		795,871,000	$ 373,281,000	$ 437,072,000
ALS Biopharma And Fox Chase Chemical Diversity Center Inc | Collaborative arrangement
License agreements
Number of prodrugs of glutamate modulating agents | prodrug	300
Milestone payment to be paid upon regulatory achievement		4,000,000
Number of claims | claim	1
Research and development		$ 0	$ 0	$ 0